But the company focused on a modified intent-to-treat analysis of its pivotal trial.
With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.